Nov 15, 2023 / 03:00AM GMT
Operator
Good morning, ladies and gentlemen. Welcome to the Q2 FY '24 Earnings Conference Call of Glenmark Pharmaceuticals Limited. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Mr. Utkarsh Gandhi, General Manager, Investor Relations for Glenmark Pharmaceuticals. Thank you, and over to you, sir.
Utkarsh Gandhi -
Thank you, [Lizan]. Good morning, everyone. Welcome to the Q2 FY '24 Results Conference Call of Glenmark Pharmaceuticals Limited. We'll just review the overall performance of the company for the second quarter of FY '24. For the second quarter of FY '24, Glenmark's consolidated revenue from operations was at INR 35,879 million, as against INR 33,752 million in the corresponding quarter last year, recording an overall year-on-year growth of 6.3%. For the 6 months ended September 30, 2023, Glenmark's consolidated revenue was INR 69,895 million as against INR 61,525 million, recording an increase of 13.6%.
Some key updates on the formulation business, starting with India. Sales from the formulation
Q2 2024 Glenmark Pharmaceuticals Ltd Earnings Call Transcript
Nov 15, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers